Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Wednesday, July 23, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has received FDA Orphan Drug Designation for its gene therapy PBGENE-DMD, aimed at treating Duchenne Muscular Dystrophy. This designation highlights the therapy's potential to address a critical unmet medical need. The company employs its proprietary ARCUS platform for developing in vivo gene editing therapies.
Price reaction · baseline $4.86 (2025-07-22 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
+1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • FDA granted Orphan Drug Designation to PBGENE-DMD.
  • Potential to address a significant unmet need in Duchenne Muscular Dystrophy.
  • Precision BioSciences utilizes innovative ARCUS platform.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Jul. 23, 2025– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S.

Frequently Asked Questions

What is PBGENE-DMD?

PBGENE-DMD is a gene therapy developed by Precision BioSciences for treating Duchenne Muscular Dystrophy.

What designation did PBGENE-DMD receive?

PBGENE-DMD received FDA Orphan Drug Designation.

What is the significance of Orphan Drug Designation?

Orphan Drug Designation helps facilitate the development of therapies for rare diseases.

What platform does Precision BioSciences use?

Precision BioSciences utilizes its proprietary ARCUS platform for gene editing.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences Duchenne Muscular Dystrophy PBGENE-DMD FDA Orphan Drug gene therapy
Last updated: Jul 23, 2025

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →